Disease · MONDO_0019496
neuroendocrine neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. neuroendocrine neoplasm. Diseases, record MONDO_0019496. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019496
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 9 of its 145 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and PMDA
- Open Targets
Drugs145
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Approval | ClinicalTrials.gov, DailyMed, EMA Human Drugs and FDA | 31 | 28 | 20 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Approval | DailyMed | 25 | 24 | 24 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| TELOTRISTAT ETHYL | CHEMBL2105695 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| SUNITINIB | CHEMBL535 | Small molecule | Approval | EMA Human Drugs | 5 | 3 | 3 | Drugs and targets |
| EDOTREOTIDE | CHEMBL408350 | Small molecule | Approval | EMA Human Drugs | 3 | 2 | 1 | Drugs and targets |
| STREPTOZOCIN | CHEMBL1977579 | Small molecule | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| COPPER OXODOTREOTIDE CU-64 | CHEMBL4297339 | Protein | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| SUNITINIB MALATE | CHEMBL1567 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
1 to 10 of 145
See all 145 drugsTargets213
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 9 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 8 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 8 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 8 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 8 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 7 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6755 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 6 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5156 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 6 | Somatostatin receptor 1 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6751 | Drugs and targets |
1 to 10 of 213
See all 213 targetsTrials200
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00412061 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | Phase 3 | 429 | 2012-03-12 | Carcinoid Tumor, Malignant Carcinoid Syndrome | EVEROLIMUS, OCTREOTIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | Phase 3 | 427 | 2016-04-28 | Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2 | BEVACIZUMAB, OCTREOTIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Phase 2 | 345 | 2021-11-22 | Advanced Solid Tumors | LURBINECTEDIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | Phase 3 | 302 | 2016-12-28 | Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Phase 3 | 298 | 2024-10-16 | Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours | Phase 3 | 264 | 2015-02-18 | Endocrine Tumors | LANREOTIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01595009 | An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) | Phase 4 | 246 | 2018-11-29 | Neuroendocrine Tumors | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02937116 | First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors | Phase 1 | 233 | 2021-02-21 | Cancer, Solid Tumor | CAPECITABINE, CISPLATIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, PEMETREXED, SINTILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03095274 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin | Phase 2 | 126 | 2025-01-09 | Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | DURVALUMAB, TREMELIMUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02955069 | Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) | Phase 2 | 116 | 2021-04-12 | Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma | SPARTALIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 200
See all 200 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Octreotide, Bevacizumab vs Octreotide, Interferon Alpha-2b: serious adverse events | 68 of 197 | 9 of 194 | 391 | NCT00569127 | Trial comparisons |
| Lanreotide (Autogel Formulation) vs Placebo: serious adverse events | 25 of 101 | 32 of 103 | 204 | NCT00353496 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause | 9 of 76 | 18 of 76 | 152 | NCT03365791 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events | 31 of 76 | 4 of 76 | 152 | NCT03365791 | Trial comparisons |
| Well-differentiated NET vs Poorly-differentiated GEP-NEC: PDR001 Anti-drug Antibodies (ADA) Prevalence at Baseline | 1 of 88 | 0 of 17 | 105 | NCT02955069 | Trial comparisons |
| Well-differentiated NET vs Poorly-differentiated GEP-NEC: PDR001 ADA Incidence On-treatment | 10 of 84 | 2 of 17 | 101 | NCT02955069 | Trial comparisons |
| Octreotide LAR (SMS995) vs Placebo: serious adverse events | 11 of 42 | 10 of 43 | 85 | NCT00171873 | Trial comparisons |
| Placebo + SSA vs Xermelo + SSA: deaths from any cause | 1 of 35 | 0 of 32 | 67 | NCT04810091 | Trial comparisons |
| Placebo + SSA vs Xermelo + SSA: serious adverse events | 3 of 35 | 4 of 32 | 67 | NCT04810091 | Trial comparisons |
| Carcinoid Tumor vs Islet Cell Carcinoma: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | 31 of 31 | 12 of 12 | 43 | NCT00781911 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials118
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019496
GET https://conductscience.org/api/diseases/v1/MONDO_0019496/drugs?page=2